{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T20:28:19Z","timestamp":1770496099651,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40261-024-01345-3","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T13:02:09Z","timestamp":1708520529000},"page":"209-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7231-1471","authenticated-orcid":false,"given":"Ryan","family":"Thaliffdeen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5238-6464","authenticated-orcid":false,"given":"Anthony","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9907-7670","authenticated-orcid":false,"given":"Karen","family":"Rascati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"1345_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/head.14024","volume":"61","author":"R Burch","year":"2021","unstructured":"Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61:60\u20138.","journal-title":"Headache"},{"key":"1345_CR2","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/13696998.2018.1457533","volume":"21","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S, et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. 2018;21:666\u201375.","journal-title":"J Med Econ"},{"key":"1345_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1\u201318.","journal-title":"Headache"},{"key":"1345_CR4","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40261-019-00827-z","volume":"39","author":"TV Giannouchos","year":"2019","unstructured":"Giannouchos TV, Mitsikostas D-D, Ohsfeldt RL, Vozikis A, Koufopoulou P. Cost-effectiveness analysis of erenumab versus onabotulinumtoxina for patients with chronic migraine attacks in Greece. Clin Drug Investig. 2019;39:979\u201390.","journal-title":"Clin Drug Investig"},{"key":"1345_CR5","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337\u201345.","journal-title":"Neurology"},{"key":"1345_CR6","first-page":"313","volume":"15","author":"T Sprenger","year":"2018","unstructured":"Sprenger T, Viana M, Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurother J Am Soc Exp Neurother. 2018;15:313\u201323.","journal-title":"Neurother J Am Soc Exp Neurother."},{"key":"1345_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.174902","volume":"922","author":"JBR Dos Santos","year":"2022","unstructured":"Dos Santos JBR, da Silva MRR. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: a review. Eur J Pharmacol. 2022;922: 174902.","journal-title":"Eur J Pharmacol"},{"key":"1345_CR8","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40263-021-00834-9","volume":"35","author":"LH Overeem","year":"2021","unstructured":"Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U. Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis. CNS Drugs. 2021;35:805\u201320.","journal-title":"CNS Drugs"},{"key":"1345_CR9","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/0333102418796842","volume":"38","author":"M Sussman","year":"2018","unstructured":"Sussman M, Benner J, Neumann P, Menzin J. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia Int J Headache. 2018;38:1644\u201357.","journal-title":"Cephalalgia Int J Headache."},{"key":"1345_CR10","unstructured":"Institute for Clinical and Economic Review. Calcitonin gene-related peptide (CGRP) inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value. 2018. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Migraine_Final_Evidence_Report_070318.pdf. Accessed 19 Feb 2024."},{"key":"1345_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695\u2013706.","journal-title":"N Engl J Med"},{"key":"1345_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2021;397:51\u201360.","journal-title":"Lancet Lond Engl."},{"key":"1345_CR13","unstructured":"Qulipta. Open-label, long-term safety study for EM: reductions observed across 52 weeks. Available from: https:\/\/www.quliptahcp.com\/continuous-control#. Accessed 19 Feb 2024."},{"key":"1345_CR14","unstructured":"Biohaven Pharmaceutical Holding Co Ltd - NEURO INNOVATION BROAD PIPELINE OF LATE STAGE PRODUCT CANDIDATES NYSE: BHVN \u00a9 2020 Biohaven Pharmaceuticals Inc. All rights reserved. Rimegepant Migraine Prevention Topline Data Webcast March 30, 2020 - EX-99.2 - March 31, 2020. Available from: https:\/\/fintel.io\/doc\/sec-bhvn-biohaven-pharmaceutical-holding-ex992-2020-march-31-18403-27. Accessed 2 Jul 2023."},{"key":"1345_CR15","unstructured":"RED BOOK search results - MICROMEDEX. Available from: https:\/\/www.micromedexsolutions.com. Accessed 5 Jun 2023."},{"key":"1345_CR16","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.37765\/ajmc.2020.42543","volume":"26","author":"M Polson","year":"2020","unstructured":"Polson M, Williams TD, Speicher LC, Mwamburi M, Staats PS, Tenaglia AT. Concomitant medical conditions and total cost of care in patients with migraine: a real-world claims analysis. Am J Manag Care. 2020;26:S3-7.","journal-title":"Am J Manag Care"},{"key":"1345_CR17","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1177\/0333102411425960","volume":"31","author":"RP Insinga","year":"2011","unstructured":"Insinga RP, Ng-Mak DS, Hanson ME. Costs associated with outpatient, emergency room and inpatient care for migraine in the USA. Cephalalgia Int J Headache. 2011;31:1570\u20135.","journal-title":"Cephalalgia Int J Headache."},{"key":"1345_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s41669-018-0105-0","volume":"3","author":"JK Porter","year":"2019","unstructured":"Porter JK, Di Tanna GL, Lipton RB, Sapra S, Villa G. Costs of acute headache medication use and productivity losses among patients with migraine: insights from three randomized controlled trials. PharmacoEconomics Open. 2019;3:411\u20137.","journal-title":"PharmacoEconomics Open."},{"key":"1345_CR19","unstructured":"Bureau of Labor Statistics. Real Earnings - December 2021. Available from: https:\/\/www.bls.gov\/news.release\/archives\/realer_01122022.pdf. Accessed 5 Jul 2023."},{"key":"1345_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/M20-1392","volume":"174","author":"DJ Vanness","year":"2021","unstructured":"Vanness DJ, Lomas J, Ahn H. A health opportunity cost threshold for cost-effectiveness analysis in the United States. Ann Intern Med. 2021;174:25\u201332.","journal-title":"Ann Intern Med"},{"key":"1345_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1021\/acsptsci.9b00061","volume":"2","author":"CT King","year":"2019","unstructured":"King CT, Gegg CV, Hu SN-Y, Sen LuH, Chan BM, Berry KA, et al. Discovery of the migraine prevention therapeutic aimovig (erenumab), the first fda-approved antibody against a G-protein-coupled receptor. ACS Pharmacol Transl Sci. 2019;2:485\u201390.","journal-title":"ACS Pharmacol Transl Sci."},{"key":"1345_CR22","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/j.1526-4610.2005.05182.x","volume":"45","author":"JS Brown","year":"2005","unstructured":"Brown JS, Papadopoulos G, Neumann PJ, Friedman M, Miller JD, Menzin J. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache. 2005;45:1012\u201322.","journal-title":"Headache"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01345-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01345-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01345-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T09:04:42Z","timestamp":1709543082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01345-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1345"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01345-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"assertion":[{"value":"22 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for conducting this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"The Institutional Review Board at the University of Texas at Austin has determined that this study does not involve human subjects.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"RT, AY, and KR were responsible for conceptualization; RT, AY, and KR for methodology; RT and AY for data curation; RT, AY, and KR for formal analysis; RT, AY, and KR for visualization; RT and AY for writing\u2013original draft; and RT, AY, and KR for writing\u2014review and editing. All authors have read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}